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BUSM AND BCH STUDY SHOWS DDI HOLDS PROMISE AS ANTI-AIDS TREATMENT 
Boston, Mass.--In a Phase I c l i n i c a l t r i a l , researchers have found the 
drug ddl (dideoxyinosine) to be a promising a n t i - v i r a l treatment f o r AIDS, but 
without some of the more serious side effects of AZT, the only a n t i - v i r a l drug 
currently approved by the Food and Drug Administration (FDA) for use i n AIDS 
patients. This finding suggests that ddl may be an effect i v e alternative 
treatment, especially for patients who cannot tolerate AZT. The study i s 
reported i n the May 10 New England Journal of Medicine. 
Ddl i s a member of the same chemical group as AZT and works i n the same 
manner, by i n h i b i t i n g an enzyme necessary f o r r e p l i c a t i o n of the AIDS v i r u s , 
HIV. AZT may be associated with serious side e f f e c t s , the most s i g n i f i c a n t 
being suppression of blood c e l l s , which may resul t i n the need for 
transfusions or discontinuation of the drug. Researchers at Boston University 
School of Medicine (BUSM) and Boston City Hospital (BCH) tested ddl i n a group 
of AIDS patients to determine i f ddl would be e f f e c t i v e , but without the side 
effects of AZT. 
In the BUSM/BCH study, 34 patients with AIDS or AIDS-related complex were 
given ddl once d a i l y at six d i f f e r e n t dosage levels f or a median of 12 weeks. 
Doses were based on individual body weights. 
Overall, ddl was found to have an acceptable t o x i c i t y p r o f i l e with a 
maximum tolerated d a i l y dosage of 20.4 mg. per kilogram. The most serious 
side effects included nerve damage that caused painful feet i n one patient and 
inflammation of the pancreas i n two patients. Although there were other less 




c e l l s or anemia associated with AZT. Overall there was a s i g n i f i c a n t 
improvement i n blood counts after treatment with ddl, even among patients who 
did not tolerate AZT. 
In evaluating the drug's efficacy, researchers found that after 10 weeks, 
there was a s i g n i f i c a n t increase i n the T4 lymphocytes--the white blood c e l l s 
infected by the AIDS virus and responsible f o r the infectious complications of 
the disease. They also found a s t a t i s t i c a l l y s i g n i f i c a n t decrease i n the H I V 
antigen marker that r e f l e c t s the level of the virus i n the bloodstream. The 
decrease was more than 50 percent i n 14 to 19 patients. 
In addition, 85 percent of the patients reported increase i n energy and 
appetite and had a s t a t i s t i c a l l y s i g n i f i c a n t increase i n weight gain af t e r six 
weeks. No patient developed an AIDS-related opportunistic infection after 
being on the drug f o r six weeks. 
"This study shows that ddl has an acceptable t o x i c i t y p r o f i l e that i s 
d i f f e r e n t from AZT," said Timothy Cooley, M.D., a co-investigator of the 
study, who i s an assistant professor at BUSM and a member of the C l i n i c a l AIDS 
Service at BCH. "We're hopeful that the preliminary results showing efficacy 
are c l i n i c a l l y signfleant, with a decrease i n major infections and improved 
su r v i v a l . This would make ddl a reasonable alternative to treatment with AZT, 
p a r t i c u l a r l y for those patients who are intolerant or unresponsive to AZT." 
Cooley cautions that although the study showed the drug to have some 
anti-HIV a c t i v i t y , the results are preliminary, and further studies are needed 
to confirm i t s efficacy and to compare i t more d i r e c t l y with AZT. 
Ddl i s now being compared to AZT i n Phase I I t r i a l s sponsored by the AIDS 
C l i n i c a l T r i a l s Group (ACTG). The ACTG i s also supporting a t r i a l giving ddl 
to patients i n t o l e r a n t to AZT. In addition, ddl i s being given to 
approximately 8000 patients as part of the FDA's new parallel-track policy 
established l a s t f a l l , i n which patients not e l i g i b l e f o r studies may be given 
ddl \diile the investigation continues. 
Boston City Hospital i s a princ i p a l teaching hospital of Boston University 
School of Medicine. 
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